Adam Capital PLC


Adam Capital PLC

Health CarePharmaceuticals & Biotechnology
  • Price (LKR)0.90
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-40.00%
  • Beta1.6045
Data delayed at least 15 minutes.
More ▼

Profile data is unavailable for this security.

About the company

Adam Capital PLC is a Sri Lanka-based investment holding company. The Company is engaged in the business of assembling and selling of all types of computers and electronic equipment, and investing in quoted shares. The Company's segments include Investments, Activated Carbon, Micro Credit, Intra Group and Group. The Company's subsidiaries include Adam Carbons (Pvt) Ltd and Adam Capital Micro Credit (Pvt) Ltd. Adam Carbons (Pvt) Ltd is a manufacturer of granular activated carbon, powdered activated carbon and its solutions from coconut shell and coconut charcoal in Sri Lanka. Its activated carbon is used in various industries, such as potable water treatment, pharmaceutical, industrial water and waste water treatment, air purification, gold recovery, metal refineries and mining. Adam Capital Micro Credit (Pvt) Ltd provides micro credit facilities to the members of the under-served communities in the urban and the semi-urban areas of Colombo and throughout the Island.

  • Revenue in LKR (TTM)403.63m
  • Net income in LKR57.87m
  • Incorporated2008
  • Employees3.60k
  • Location
    Adam Capital PLC264, Grandpass Road,, Colombo 14COLOMBO 03Sri LankaLKA
  • Phone+94 117608500
  • Fax+94 112447886
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Black Star Petroleum Ltd220.00-4.27m1.59m--------7,227.45-0.0081-0.00810.00-0.00080.00008--0.0359---146.07-45.71-210.53-50.21-----1,940,150.00-13,151.36---26.65-----40.74--32.67------
Ephraim Resources Ltd119.60k-757.25k1.63m20.00--1.52--13.59-0.0005-0.00050.000080.00130.0393--1.45---24.94-32.63-28.84-38.25-----634.31-1,419.80---153.680.1896--653.9237.778.69------
FYI Resources Ltd11.25k-963.50k1.85m0.00--7.92--164.29-0.0108-0.01080.00010.00250.0135--0.1299---124.23-41.92-218.00-47.99-----9,172.53-4,833.65----0.00--70.61-29.3360.34------
PharmaNet Group Limited0.00252.47k1.89m1.00----7.34--0.03260.03260.00-0.61790.00------8,359.93-165.78-------67.72---548.77---------100.00--120.56------
BPH Energy Ltd204.35k-568.91k2.35m2.00k--0.0698--11.50-0.002-0.0020.00070.05740.009--34.99---2.68-13.38-2.93-13.72-----296.22-2,592.30---2.850.043---19.01-21.3798.08------
SciGen Limited38.63m2.73m2.61m41.0010.14--0.80910.06760.00490.00490.07-0.13391.065.662.72--7.462.978.444.7552.9654.
Ankur Drugs and Pharma Ltd.1.41bn-3.33bn74.27m1.25k------0.0525-172.32-172.3273.12--------1,135,887.00---2.83---3.9925.3420.23-235.66-5.14---1.72-----81.63-16.49-346.89---71.05--
Twilight Litaka Pharma Ltd6.72bn512.47m104.63m1.74k----0.18890.015624.0824.08315.6472.261.564.973.02--11.91--19.07--41.72--7.63--
Adam Capital PLC403.63m57.87m226.80m3.60k3.920.37081.990.56190.22970.22971.602.430.34221.802.68--4.912.616.685.6422.6515.0414.344.650.85484.390.3713-----19.36107.45-46.9060.72--
Data as of --. Currency figures normalised to Adam Capital PLC's reporting currency: Sri Lankan Rupee LKR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.